Tunisian Pharmaceutical Laboratory Unimed Forecasts 165 Million Dinars in Revenue for 2025, a 12% Increase from 2024
Presenting the group's results and prospects, Deputy General Manager Mohamed Ali Akkari highlighted a sustained growth dynamic at all levels, driven by a strategy focused on export, innovation, and industrial investments.
Growth Across All Indicators
After reaching 147 million dinars in revenue in 2024, Unimed aims to achieve 27.2 million dinars in net profit in 2025, a 16% increase from the previous year. In the first six months of the year, revenues have already jumped by 15%, with a strong second quarter showing a 29% increase, exceeding budget forecasts by 12%.
In the Tunisian hospital market, Unimed ranks second behind Roche, surpassing heavyweights like Novartis and Pfizer. It is also the leading supplier of medicines to the state. Its growth in this segment reaches 25.79% in the first half, compared to a market average of 12.14%. In the private pharmacy circuit, Unimed occupies the 10th position, but its growth of 17.28% exceeds the market average of 12.76%. In terms of volume, it ranks third in the combined market (hospital and pharmacy), with an industrial performance significantly above the average.
Export and Innovation Strategy
Specialized in sterile and injectable medicines, Unimed benefits from numerous international certifications (EMA, ANSM, GMP, CE, etc.). It relies on partnerships with major laboratories and develops its own products to strengthen its presence abroad.
Unimed aims to reduce the share of subcontracting in exports (currently 65%) in favor of its own products. Marketing authorizations have been obtained or filed in Mauritania (11), Oman (16), Burkina Faso, and Togo (66), with 23 additional ones recently added. The goal is to generate 110 million dinars in export revenue over three years, with ongoing negotiations in several African countries.
Massive Investments and Structuring Projects
Between 2025 and 2026, Unimed plans to invest 39 million dinars, allocated to:
- A packaging line (2.2 MDT)
- A solar station covering 40% of electricity needs
- Maintenance and modernization works (4 MDT)
- Equipment for the development of new molecules (400 MDT announced)
- The extension of the Unimed 2 site, featuring 25,000 m² of clean rooms, at a cost of 62 MDT
Furthermore, advanced discussions are underway with an international partner for a 10-year contract, which would include an investment of 18 million dinars in machines destined for export to Europe and America.
With this ambitious roadmap, Unimed consolidates its position as a national leader while affirming its ambitions to become a regional pharmaceutical player.
